Sandbox:Hannan: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Hannan Javed (talk | contribs) No edit summary |
||
Line 7: | Line 7: | ||
! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |Myeloproliferative neoplasms (MPN) | ! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |Myeloproliferative neoplasms (MPN) | ||
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations | ! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations | ||
! colspan=" | ! colspan="13" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis | ||
! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |Other features | ! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |Other features | ||
|- | |- | ||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptoms | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptoms | ||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Physical examination | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Physical examination | ||
! colspan=" | ! colspan="10" style="background:#4479BA; color: #FFFFFF;" align="center" + |Lab findings | ||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Bone marrow biopsy | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Bone marrow biopsy | ||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Gold standard | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Gold standard | ||
! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Other investigations | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" + |Other investigations | ||
|- | |- | ||
! colspan=" | ! colspan="7" |WBCs | ||
! rowspan="2" |RBCs | ! rowspan="2" |RBCs | ||
! colspan="2" rowspan="2" |Platelets | ! colspan="2" rowspan="2" |Platelets | ||
|- | |- | ||
! | !<small>Leukocytosis</small> | ||
!<small>Blasts</small> | !<small>Blasts</small> | ||
!<small>Left shift</small> | !<small>Left shift</small> | ||
Line 51: | Line 51: | ||
* <small>priapism</small> | * <small>priapism</small> | ||
|<small>absolute leukocytosis</small> <small>(median of 100,000/µL)</small> | |||
|<small>blasts usually <2%</small> | |<small>blasts usually <2%</small> | ||
| | | | ||
Line 69: | Line 69: | ||
| | | | ||
| | | | ||
|- | |- | ||
|Chronic neutrophilic leukemia (CNL) | |Chronic neutrophilic leukemia (CNL) | ||
| | | | ||
| | | | ||
Line 95: | Line 89: | ||
|- | |- | ||
|Polycythemia vera (PV) | |Polycythemia vera (PV) | ||
| | | | ||
| | | | ||
Line 119: | Line 109: | ||
* <small>prefibrotic/early stage</small> | * <small>prefibrotic/early stage</small> | ||
* <small>overt fibrotic stage</small> | * <small>overt fibrotic stage</small> | ||
| | | | ||
| | | | ||
Line 141: | Line 127: | ||
|- | |- | ||
|Essential thrombocythemia (ET) | |Essential thrombocythemia (ET) | ||
| | | | ||
| | | | ||
Line 163: | Line 145: | ||
|- | |- | ||
|Chronic eosinophilic leukemia, not otherwise specified (NOS) | |Chronic eosinophilic leukemia, not otherwise specified (NOS) | ||
| | | | ||
| | | | ||
Line 185: | Line 163: | ||
|- | |- | ||
|MPN, unclassifiable | |MPN, unclassifiable | ||
| | | | ||
| | | | ||
Line 207: | Line 181: | ||
|- | |- | ||
|Mastocytosis | |Mastocytosis | ||
| | | | ||
| | | |
Revision as of 18:51, 15 January 2019
Myeloproliferative neoplasms (MPN) | Clinical manifestations | Diagnosis | Other features | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | Lab findings | Bone marrow biopsy | Gold standard | Other investigations | |||||||||||
WBCs | RBCs | Platelets | ||||||||||||||
Leukocytosis | Blasts | Left shift | Basophilia | Eosinophilia | Monocytosis | Others | ||||||||||
Chronic myeloid leukemia
(CML), BCR-ABL1+ |
Asymptomatic
Non-specific Hyperviscosity related Anemia related Bleeding Infection |
|
absolute leukocytosis (median of 100,000/µL) | blasts usually <2% |
|
absolute basophilia is almost always present | absolute eosinophilia in 90% of patients | often present | Anemia |
|
Bone marrow aspirate and unilateral biopsy with conventional cytogenetics and flow cytometry | |||||
Chronic neutrophilic leukemia (CNL) | ||||||||||||||||
Polycythemia vera (PV) | ||||||||||||||||
Primary myelofibrosis (PMF)
|
||||||||||||||||
Essential thrombocythemia (ET) | ||||||||||||||||
Chronic eosinophilic leukemia, not otherwise specified (NOS) | ||||||||||||||||
MPN, unclassifiable | ||||||||||||||||
Mastocytosis |
Other myeloid neoplasm and acute leukemia | Clinical manifestations | Diagnosis | Other features | ||||
---|---|---|---|---|---|---|---|
Symptoms | Physical examination | Lab findings | Bone marrow biopsy | Gold standard | Other investigations | ||
Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of
PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2
|
|||||||
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
|
|||||||
Myelodysplastic syndromes (MDS)
|
|||||||
Acute myeloid leukemia (AML) and related neoplasms
|
|||||||
Blastic plasmacytoid dendritic cell neoplasm | |||||||
Acute leukemias of ambiguous lineage
|
|||||||
B-lymphoblastic leukemia/lymphoma
|
|||||||
T-lymphoblastic leukemia/lymphoma
|
- 50% of patients are asymptomatic
- Clinical features are generally nonspecific such as left upper quadrant pain, early satiety, fatigue & lethargy (most common presenting symptom), weight loss, and night sweats.
- symptoms of anemia
- bleeding
- priapism
- bone pain
- Abdominal mass or fullness
- Infection
- Headache
- Dyspnoea
- Visual disturbances
- Weakness
- Arthralgia
- Cough
- Malaise
- Dizziness
- Nausea/vomiting
- Ankle oedema
- Mental change